Skip to main content
. 2012 Oct 15;7(10):e47115. doi: 10.1371/journal.pone.0047115

Figure 4. 5-FU nanoparticle had liver-targeting and enhanced 5-FU to inhibit the growth of hepatic caner through ASGPR in vivo.

Figure 4

(A) Expression of ASGPR mRNA in different tissues of hepatic cancer, liver, spleen, kidney, lung, muscle, heart and bowel in the orthotropic liver cancer mouse model evaluated by RT-PCR. Results are shown as means±SD (n = 3). (**P<0.01, compared with spleen, kidney, lung, muscle, heart and bowel; ## P<0.01, compared with liver). (B) 5-FU concentration in different tissues in mice were treated with i.v. 5-FU, CS/5-FU or GC/5-FU or, 5-FU determined 30 min post-injection. Results are shown as an means±SD (n = 3). Hepatic cancer tissue showed the highest 5-FU concentration, followed by liver tissue. (C) The ratio of 5-FU concentration in hepatic cancer cells relative to that in other tissues. The 5-FU concentration in hepatic cancer was 8.69-, 23.35-, 79.96- and 85.15-fold higher than that in normal liver tissue, kidney, heart and blood, respectively. (D) The weight of liver tumors measured on Day 10. Results are shown as means±SD deviation (n = 10). Mice received GC/5-FU,CS/5-FU, 5-FU, GC or PBS on Day 5 after establishing the transplant model. **P<0.01 compared to control or GC group; ##P<0.01 compared to 5-FU group, ▴P<0.05 compared to CS/5-FU group. (E)Body weight was monitored from Day 1 to 10 of treatment (n = 10). Body weigh decreased significantly more in the 5-FU group compared with the control, GC, CS/5-FU and GC/5-FU group. There was no difference in body weight between the GC/5-FU, CS/5-FU, GC and control groups. (F) Mouse survival. The median survival in the control, GC, 5-FU, CS/5-FU and GC/5-FU groups was 16, 17, 22, 29 and 35 days, respectively. The longest median survival time was seen in the GC/5-FU group.